Rocket One (RKTO) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rocket One (RKTO) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 72.6% versus a loss of 96.4%. Over five years, RKTO leads with a -98.6% price change compared with -99.7% for VTGN. Vistagen Therapeutics is the larger company by market cap ($7.6 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RKTO | VTGN |
|---|---|---|
| Share price | $0.297 | $0.1636 |
| Market cap | $7.39M | $7.56M |
| 1-day change | +5.24% | -12.33% |
| YTD return | -70.00% | -75.21% |
| 1-year return | -72.63% | -96.44% |
| 5-year return | -98.60% | -99.72% |
| EPS (TTM) | $-0.82 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.27M |
| Revenue growth (YoY) | — | +161.11% |
| Net income (latest FY) | $-12.47M | $-69.69M |
| Operating margin | — | -5683.69% |
| Net margin | — | -5491.33% |
| 52-week high | $2.45 | $5.14 |
| 52-week low | $0.26 | $0.16 |
| Distance from 52-week high | -87.88% | -96.82% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +511.25% |
| Average volume | 338.12K | 10.30M |
| Shares outstanding | 24.90M | 46.19M |
| Employees | 2 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RKTO has outperformed VTGN by 23.8 percentage points over the past year.
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
RKTO vs VTGN FAQ
Which is bigger, Rocket One or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $7.56M compared with $7.39M for Rocket One (RKTO).
Which stock has performed better over the past year, RKTO or VTGN?
RKTO returned -72.63% over the past 12 months, compared with -96.44% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Rocket One and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.